Spotlight on the Oncology Pipeline

ACPE UAN #:  0233-9999-17-047-H01-P

Release Date:  October 17, 2017

Expiration Date:  October 17, 2020

Activity Type:    Knowledge-based

Contact HoursPhysicians: 1.5 AMA PRA Category 1 Credit™ | Nurses: 1.5 contact hours |  Pharmacists: 1.5 contact hours

Activity Fee:  Member:  $15        Non-Member: $30

Target Audience: Pharmacists who practice in managed care settings, physicians, and nurses.

Activity Overview

With the recent emphasis and success of immune checkpoint inhibitors for the treatment of various tumor types, it is tempting to assume that the oncology pipeline exclusively focuses on immunotherapies. However, new pharmacologic therapies are being developed for several important malignant pathways. Drugs that target these pathways will likely dramatically impact the overall treatment landscape due to their expected effect on improving patient outcomes. High utilization also is expected due to the fact that many of these pathways are not specific to one tumor type.

This session will focus on emerging oncologic therapies likely to be approved by the U.S. Food and Drug Administration (FDA) in 2018. Faculty will explain the mechanisms of action, potential indication and dosing, and adverse effects, as well as present the status of the evidence surrounding these agents. Treatment guidelines and recommendations will be discussed in context of how these agents may change clinical practice. This session will conclude with a forecast of how these therapies will influence overall drug and biologic expenditures in the U.S.

Learning Objectives:  

At the completion of this activity, participants should be able to:

1. Identify at least three oncologic therapies likely to be FDA- approved in 2018 that have the potential to improve patient outcomes and change clinical treatment guidelines.

2. Discuss the existing and emerging evidence with oncologic therapies likely to be FDA-approved in 2018 and how this evidence may influence future guideline updates and managed care pharmacy teams.

3.  Summarize the potential impact of emerging oncologic therapies on overall drug and biologic expenditures. 

Schedule of Educational Activity

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation. 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP Nexus 2017. 

CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  •  Review the full content of the activity.
  •  Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  •  Complete a specific activity evaluation.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and be navigating websites.  View the minimum technical and system requirements for continuing education online learning activities.


The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities.  It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

Physicians:  PRIME Education, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians   

Nurses:   PRIME Education, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


Laura Bartels-Peculis, PharmD | Senior Health Economics and Outcomes Research Liaison | Mallinckrodt Pharmaceuticals | Bedminster Township, New Jersey

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-9999-17-047-H01-P 1.5 Contact Hours October 17, 2017 - October 17, 2020